First UK patient receives coronavirus trial drug
The patient is part of the Oscar study conducted by GlaxoSmithKline, set up to investigate whether one of its pipeline drugs, Otilimab, can help reduce the effects of the so-called cytokine storm a severe immune reaction where the body starts to attack its own cells which was found to occur in some hospitalized coronavirus patients.
The drug is a monoclonal antibody that was already in late-stage clinical trials and was originally considered as a potential new treatment for rheumatoid arthritis.
The patient is being treated at the Manchester Royal Infirmary, part of the Manchester University NHS Foundation Trust, and was recruited to the study on Sept. 11. ■